Adaptive Biotechnologies Management

Management criteria checks 2/4

Adaptive Biotechnologies' CEO is Chad Robins, appointed in Sep 2009, has a tenure of 14.75 years. total yearly compensation is $8.90M, comprised of 7.4% salary and 92.6% bonuses, including company stock and options. directly owns 1.23% of the company’s shares, worth €5.78M. The average tenure of the management team and the board of directors is 5.3 years and 8.4 years respectively.

Key information

Chad Robins

Chief executive officer

US$8.9m

Total compensation

CEO salary percentage	7.4%
CEO tenure	14.8yrs
CEO ownership	1.2%
Management average tenure	5.3yrs
Board average tenure	8.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chad Robins's remuneration changed compared to Adaptive Biotechnologies's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$215m
Dec 31 2023	US$9m	US$663k	-US$225m
Sep 30 2023	n/a	n/a	-US$196m
Jun 30 2023	n/a	n/a	-US$191m
Mar 31 2023	n/a	n/a	-US$195m
Dec 31 2022	US$9m	US$658k	-US$200m
Sep 30 2022	n/a	n/a	-US$221m
Jun 30 2022	n/a	n/a	-US$232m
Mar 31 2022	n/a	n/a	-US$229m
Dec 31 2021	US$9m	US$639k	-US$207m
Sep 30 2021	n/a	n/a	-US$190m
Jun 30 2021	n/a	n/a	-US$171m
Mar 31 2021	n/a	n/a	-US$155m
Dec 31 2020	US$7m	US$597k	-US$146m
Sep 30 2020	n/a	n/a	-US$122m
Jun 30 2020	n/a	n/a	-US$99m
Mar 31 2020	n/a	n/a	-US$82m
Dec 31 2019	US$3m	US$493k	-US$70m
Sep 30 2019	n/a	n/a	-US$62m
Jun 30 2019	n/a	n/a	-US$56m
Mar 31 2019	n/a	n/a	-US$53m
Dec 31 2018	US$3m	US$423k	-US$46m

Compensation vs Market: Chad's total compensation ($USD8.90M) is above average for companies of similar size in the German market ($USD1.05M).

Compensation vs Earnings: Chad's compensation has increased whilst the company is unprofitable.

CEO

Chad Robins (49 yo)

14.8yrs

Tenure

US$8,904,267

Compensation

Mr. Chad M. Robins, M.B.A., serves as Independent Director at CM Life Sciences III Inc. since April 07, 2021. He serves as an Independent Director at ARYA Sciences Acquisition Corp II since June 2020. He c...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Chad Robins	Co-Founder	14.8yrs	US$8.90m	1.23% $ 5.8m
Julie Rubinstein	President & COO	6.3yrs	US$2.97m	0.32% $ 1.5m
Harlan Robins	Co-Founder & Chief Scientific Officer	14.8yrs	US$8.61m	0.69% $ 3.3m
Sharon Benzeno	Chief Commercial Officer of Immune Medicine	6.3yrs	US$2.88m	0.22% $ 1.0m
Christopher Carlson	Founder	no data	no data	no data
Kyle Piskel	VP, CFO & Principal Accounting Officer	2.7yrs	US$1.66m	0.10% $ 492.5k
Karina Calzadilla	Vice President of Investor Relations	no data	no data	no data
Stacy Taylor	Senior VP	5.3yrs	no data	0.11% $ 529.9k
Francis Lo	Chief People Officer	5.2yrs	no data	0.17% $ 816.5k
Susan Bobulsky	Chief Commercial Officer of MRD	3.8yrs	no data	0.17% $ 791.1k
Mary Lancelotta	Senior Vice President of MRD BioPharma	less than a year	no data	no data

5.3yrs

Average Tenure

49.5yo

Average Age

Experienced Management: 1HM's management team is seasoned and experienced (5.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Chad Robins	Co-Founder	14.8yrs	US$8.90m	1.23% $ 5.8m
Peter Neupert	Lead Independent Director	10.5yrs	US$355.00k	0.094% $ 439.6k
H. Parker	Member of Corporate Advisory Board	no data	no data	no data
Michelle Griffin	Independent Director	5.3yrs	US$330.00k	0.035% $ 165.6k
Robert Hershberg	Independent Director	11.3yrs	US$325.00k	0.052% $ 242.1k
Michael Pellini	Independent Director	6.3yrs	US$310.00k	0.037% $ 173.0k
Carol Gallagher	Member of Corporate Advisory Board	no data	no data	no data
Craig Weissman	Member of Corporate Advisory Board	no data	no data	no data
Graham Allen	Member of Corporate Advisory Board	no data	no data	no data
Matthew Kahn	Member of Corporate Advisory Board	no data	no data	no data
Katey Owen	Independent Director	3.3yrs	US$310.00k	0.038% $ 178.8k

8.4yrs

Average Tenure

58.5yo

Average Age

Experienced Board: 1HM's board of directors are considered experienced (8.4 years average tenure).

Adaptive Biotechnologies Management

Management criteria checks 2/4

Key information

Recent management updates

Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 07, 2024

Adaptive Biotechnologies Corporation Announces CFO Changes

Insufficient new directors

Co-Founder recently sold €154k worth of stock

Adaptive Biotechnologies Corporation Announces Executive Changes

Insufficient new directors

Recent updates

First quarter 2024 earnings released: US$0.33 loss per share (vs US$0.40 loss in 1Q 2023)

Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 07, 2024

New minor risk - Shareholder dilution

Adaptive Biotechnologies Corporation to Report Q1, 2024 Results on May 07, 2024

Adaptive Biotechnologies Corporation Announces CFO Changes

Adaptive Biotechnologies Corporation Provides Revenue Guidance for the First Quarter Ended March 31, 2024

Insufficient new directors

Co-Founder recently sold €154k worth of stock

Full year 2023 earnings released: US$1.56 loss per share (vs US$1.41 loss in FY 2022)

Full year 2023 earnings released: US$1.56 loss per share (vs US$1.41 loss in FY 2022)

Adaptive Biotechnologies Corporation to Report Q4, 2023 Results on Feb 14, 2024

Adaptive Biotechnologies Corporation and Collaborators to Present More Than 30 Abstracts Demonstrating the Actionability of ClonoSEQ MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th Annual Meeting

Adaptive Biotechnologies Corporation Updates Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$0.35 loss per share (vs US$0.32 loss in 3Q 2022)

Adaptive Biotechnologies Corporation to Report Q3, 2023 Results on Nov 09, 2023

Adaptive Biotechnologies Corporation Announces Launch of Epic Integration for ClonosEQ

Adaptive Biotechnologies Corporation Announces Executive Changes

Second quarter 2023 earnings released: US$0.33 loss per share (vs US$0.37 loss in 2Q 2022)

Adaptive Biotechnologies Corporation to Report Q2, 2023 Results on Aug 02, 2023

Adaptive Biotechnologies Corporation to Report Q2, 2023 Results on Aug 02, 2023

Insufficient new directors

New major risk - Share price stability

Adaptive Biotechnologies Corporation Announces Resignation of Leslie Trigg from the Board

Chief Financial Officer recently sold €254k worth of stock

Adaptive Biotechnologies Highlights New Data At ASCO 2023 and EHA 2023 Underscoring the Clonoseq® Assay's Impact as A Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer

Adaptive Biotechnologies Corporation Announces FDA Acceptance of Genentech's Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology

Adaptive Biotechnologies Corporation Provides Revenue Guidance for the Full Year 2023

First quarter 2023 earnings released: US$0.40 loss per share (vs US$0.44 loss in 1Q 2022)

President recently sold €182k worth of stock

Adaptive Biotechnologies Corporation Provides Revenue Guidance for Full Year 2023

Full year 2022 earnings released: US$1.41 loss per share (vs US$1.48 loss in FY 2021)

Adaptive Biotechnologies Corporation to Report Q4, 2022 Results on Feb 14, 2023

Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease in Patients with Diffuse Large B-Cell Lymphoma Using Circulating Tumor DNA

Third quarter 2022 earnings released: US$0.32 loss per share (vs US$0.40 loss in 3Q 2021)

Adaptive Biotechnologies Corporation Provides Revenue Guidance for the Full Year 2022

Adaptive Biotechnologies Corporation to Report Q3, 2022 Results on Nov 03, 2022

Chief Commercial Officer of MRD recently sold €190k worth of stock

Second quarter 2022 earnings released: US$0.37 loss per share (vs US$0.35 loss in 2Q 2021)

Adaptive Biotechnologies Corporation Reiterates Revenue Guidance for the Full Year 2022

Adaptive Biotechnologies Corporation to Report Q2, 2022 Results on Aug 03, 2022

Adaptive Biotechnologies Launches T-Detect™ Lyme, A New T-Cell Clinical Test for the Detection of Early Lyme Disease

Adaptive Biotechnologies Corporation Includes in Several Abstracts Investigating the Impact of Mrd in Blood Cancers At the American Society of Clinical Oncology

First quarter 2022 earnings released: US$0.44 loss per share (vs US$0.29 loss in 1Q 2021)

Adaptive Biotechnologies Corporation Reiterates Revenue Guidance for the Full Year 2022

Adaptive Biotechnologies Corporation, Annual General Meeting, Jun 10, 2022

Adaptive Biotechnologies Corporation to Report Q1, 2022 Results on May 04, 2022

President recently sold €51k worth of stock

Adaptive Biotechnologies Corporation Announces New Data Demonstrating ImmunoSEQ® Technology Can Identify T-Cell Receptors Associated with Crohn’s Disease

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Adaptive Biotechnologies Corporation Announces CFO Changes

Adaptive Biotechnologies Corporation Announces New Data Demonstrating the Benefit of Serial MRD Testing with the clonoSEQ® Assay in Patients with Blood Cancers at the 63rd ASH Annual Meeting

Adaptive Biotechnologies Corporation Present More than 30 Abstracts on Utility of clonoSEQ® in MRD Testing in Blood Cancer Patients at the 63rd ASH Annual Meeting

Third quarter 2021 earnings released: US$0.40 loss per share (vs US$0.27 loss in 3Q 2020)

Director Kevin Conroy has joined 4th company board

Adaptive Biotechnologies Corporation Provides Earnings Guidance for Full Year 2021

Second quarter 2021 earnings released: US$0.35 loss per share (vs US$0.26 loss in 2Q 2020)

Adaptive Biotechnologies Corporation Announces New Study Published in Nature Provides Further Evidence COVID-19 Vaccine Induced T-Cell Response Targets Known SARS-CoV-2 Variants of Concern

Adaptive Biotechnologies Corporation Provides Financial Guidance for 2021

First quarter 2021 earnings released: US$0.29 loss per share (vs US$0.25 loss in 1Q 2020)

Insider recently sold €128k worth of stock

Adaptive Biotechnologies Corporation Announces Board Changes

Independent Director has left the company

Independent Director has left the company

Adaptive Biotechnologies Announces FDA Emergency Use Authorization for T-Detect™ COVID to Confirm Recent or Prior COVID-19 Infection

New 90-day low: €33.80

Adaptive Biotechnologies Corporation and Genentech, Inc. Collaborate the Development of Cellular Therapy Drugs for Treating Cancer by Targeting Immune Cells to Specific Shared and Personalized Cancer-Related Antigen Targets

Full year 2020 earnings released: US$1.11 loss per share (vs US$1.01 loss in FY 2019)

Revenue beats expectations

Adaptive Biotechnologies Expands Collaboration with Labcorp to Increase Access to Growing Research and Clinical Diagnostic Portfolio